Immunohistochemical Biomarkers in Gastric Cancer Research and Management

Table 1

Immunohistochemical markers in GC.

IHC marker	Parameter	Reference
HER2	Prognosis	[19–23]
	Therapeutic response	[24]
	Lymph node metastasis	[25]
	Lauren histotype	[26, 27]
VEGF	Prognosis	[28–31]
	Lauren histotype	[32]
	Tumor progression	[33]
	Therapeutic response	[34]
hERG1	Prognosis	[35]
KLF5	Grading	[36]
	Stage	[36, 37]
	Lymph node status	[36, 37]
	Prognosis	[36, 37]
CA IX	Lymph node metastasis	[38]
	Prognosis	[38]
Ki67	Lymph node metastasis	[25]
PKP3	Stage	[39]
	Prognosis	[39]
MMP-2	Prognosis	[29, 31]
HDAC	Prognosis	[40–42]
Bcl-2	Lymph node metastasis	[25]
Bcl-6	Prognosis	[43]
SATB1	Lymph node metastasis	[44, 45]
	Distant metastasis	[44, 45]
	Stage	[44, 45]
c-myc2	Lymph node metastasis	[25]
TGF β	Stage	[46]
E-cadherin	Prognosis	[31, 47–52]
	Invasion	[53]
	Grading	[54, 55]
	Lauren histotype	[54]
COX-2	Prognosis	[56]
TSP-1	Prognosis	[57]
Bax	Prognosis	[58, 59]